enfortumab,Pembrolizumab,cisplatin,carboplatin,gemcitabine,Olaparib,abiraterone,Talazoparib,Enzalutamide
Astellas,Merck,Seagen,AstraZeneca,pfizer
['bladder', 'gu ', 'enfortumab', ' vedo']
watch the and chat about the latest research from #asco23 on parp inhibitors for gu cancers, along with neoadjuvant immunotherapy and enfortumab vedotin for bladder cancer: 
GU Oncology Now brings you the latest research and updates in #prostatecancer, #bladdercancer, #kidneycancer, and more in the genitourinary oncology sphere.